JPRN-UMIN000036616
Not yet recruiting
Phase 1
Juzendaihoto administration for esophageal cancer patients - Juzendaihoto administration for esophageal cancer patients
agasaki University0 sites35 target enrollmentApril 26, 2019
ConditionsEsophageal cancer
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Esophageal cancer
- Sponsor
- agasaki University
- Enrollment
- 35
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1 Cases in which preoperative chemotherapy or surgery could not be performed 2 Patients with drug hypersensitivity and allergies 3 Pregnant women and patients who may be pregnant or nursing 4 Other patients who the research director judged inappropriate as the research subject
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Study of treatment for esophageal cancerEsophageal cancerJPRN-UMIN000040909Graduate School of Medical Sciences,Kyushu University26
Not yet recruiting
Not Applicable
Prospective Multicenter Observational Study of Esophageal Preservation Survival in definitive Chemoradiotherapy +/- Photodynamic Therapy for Esophageal CancerEsophageal CancerJPRN-UMIN000043767agoya University150
Completed
Not Applicable
For advanced or recurrent esophageal cancer Of combination therapy - docetaxel-cisplatin-5 fluorouracil phase I/II trialAdvanced or recurrent esophageal cancerJPRN-UMIN000014625gifu University30
Not yet recruiting
Not Applicable
Clinical Outcomes in patients with Esophageal Cancer treated with Definitive ChemoradiotherapyHealth Condition 1: C159- Malignant neoplasm of esophagus, unspecifiedCTRI/2021/03/032343one
Active, not recruiting
Phase 1
PLAnning Treatment For Oesophago-Gastric Cancer: a Randomised Maintenance Therapy TrialOesophago-gastric adenocarcinomaTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-002169-30-GBThe Royal Marsden NHS Foundation Trust770